title: A nationwide cohort study on the incidence of meningioma in women using postmenopausal hormone therapy in Finland.
abstract: The authors conducted a nationwide cohort study to evaluate the association between postmenopausal hormone therapy and meningioma incidence in Finland. All women who had used hormone therapy at least for 6 months at the age of 50 years or older during 1994-2009 were included. Women who had used postmenopausal hormone therapy were identified from the medical reimbursement register of the Social Insurance Institution (131,480 estradiol users and 131,248 estradiol-progestin users), and meningioma cases were identified from the Finnish Cancer Registry. During the average 9 years of follow-up, 289 estradiol users and 196 estradiol-progestin users were diagnosed with meningioma. Ever use of estradiol-only therapy was associated with an increased risk of meningioma (standardized incidence ratio = 1.29, 95% confidence interval: 1.15, 1.44). Among women who had been using estradiol-only therapy for at least 3 years, the incidence of meningioma was 1.40-fold higher (95% confidence interval: 1.18, 1.64; P < 0.001) than in the background population. In contrast, this risk was not increased in users of combination therapy (standardized incidence ratio = 0.93, 95% confidence interval: 0.80, 1.06). There was no difference in risk between continuous and sequential use of hormone therapy. Estradiol-only therapy was accompanied with a slightly increased risk of meningioma.
authors.affiliation: Department of Neurosurgery, Turku University Hospital, Finland. katariina.korhonen@tyks.fi
authors.forename: Katariina
authors.initials: K
authors.lastname: Korhonen
authors.forename: Anssi
authors.initials: A
authors.lastname: Auvinen
authors.forename: Heli
authors.initials: H
authors.lastname: Lyytinen
authors.forename: Olavi
authors.initials: O
authors.lastname: Ylikorkala
authors.forename: Eero
authors.initials: E
authors.lastname: Pukkala
mesh_terms: D000368:Aged; D000369:Aged, 80 and over; D015331:Cohort Studies; D004338:Drug Combinations; D004958:Estradiol / Q000009:adverse effects*; D015914:Estrogen Replacement Therapy / Q000009:adverse effects*; D004967:Estrogens / Q000009:adverse effects*; D005260:Female; D005387:Finland / Q000453:epidemiology; D006801:Humans; D015994:Incidence; D008577:Meningeal Neoplasms / Q000139:chemically induced* / Q000453:epidemiology; D008579:Meningioma / Q000139:chemically induced* / Q000453:epidemiology; D008875:Middle Aged; D016012:Poisson Distribution; D011372:Progestins / Q000009:adverse effects*; D012042:Registries; D012044:Regression Analysis; D012306:Risk
chemical_list: D004338:Drug Combinations; D004967:Estrogens; D011372:Progestins; D004958:Estradiol